Invasive melanoma is a skin cancer that has grown beyond the outermost layer of skin (the epidermis) and penetrated into the deeper layer called the dermis. This distinction matters because once melanoma cells reach the dermis, they gain access to blood vessels and lymphatic channels, giving them the potential to spread to other parts of the body. By contrast, melanoma that remains confined to the epidermis is called melanoma in situ, which carries virtually no risk of spreading.
The word “invasive” can sound alarming, but it covers a wide spectrum. Some invasive melanomas are caught very early, are thinner than a millimeter, and have an excellent prognosis. Others are thicker, have already reached nearby lymph nodes, and require more aggressive treatment. Understanding where yours falls on that spectrum is the key to knowing what comes next.
How Invasive Melanoma Differs From Melanoma In Situ
Your skin has two main layers. The epidermis is the thin outer barrier you can see and touch. Beneath it sits the dermis, a thicker layer packed with blood vessels, lymph channels, nerve endings, and connective tissue. Melanoma in situ means abnormal melanocytes (the pigment-producing cells) are multiplying within the epidermis but haven’t crossed the boundary into the dermis. Because there are no blood or lymph vessels in the epidermis, in situ melanoma can’t metastasize.
Once those cells push past the basement membrane and enter the dermis, the melanoma is classified as invasive. Even a fraction of a millimeter of dermal invasion changes the clinical picture, because the tumor now has a theoretical route to travel elsewhere. That said, not every invasive melanoma will spread. Some researchers have identified a pool of indolent melanomas that display dermal invasion yet appear to lack the capacity for metastasis. This is why depth of invasion, not just the presence of invasion, drives treatment decisions.
Breslow Depth and How Staging Works
The single most important measurement in an invasive melanoma diagnosis is Breslow depth: the distance in millimeters from the skin surface to the deepest point of the tumor. This number, along with whether the tumor surface is ulcerated (broken down), determines the T-category stage.
- Stage I: The tumor is less than 1 mm deep, with or without ulceration. Tumors under 0.8 mm without ulceration are classified as stage IA and considered early and thin.
- Stage II: The tumor is deeper than 1 mm. Melanomas greater than 4.0 mm carry a very high risk of spreading, and ulceration can push the disease into a higher substage.
- Stage III: The cancer has reached nearby lymph nodes or developed satellite lesions in the surrounding skin. At this point, the thickness of the original tumor no longer determines the stage.
- Stage IV: The cancer has spread to distant organs.
Under the current (8th edition) staging system from the American Joint Committee on Cancer, Breslow thickness and ulceration are the two factors that define T-category. An older metric called mitotic rate, which measures how quickly tumor cells are dividing, is no longer used to assign T-category but is still documented because it remains a significant predictor of outcomes at every thickness.
The Main Types of Invasive Melanoma
Not all invasive melanomas look or behave the same way. The two most common subtypes are superficial spreading melanoma and nodular melanoma.
Superficial spreading melanoma is the most frequently diagnosed form. It tends to grow outward across the skin surface (the radial growth phase) before eventually pushing downward into deeper tissue. This horizontal spread often gives people more time to notice the lesion before it becomes dangerous. It can appear as an irregularly bordered, multicolored flat or slightly raised patch.
Nodular melanoma skips the prolonged radial phase and grows vertically from the start. Because it dives deeper faster, it’s typically thicker at diagnosis and carries a worse prognosis stage for stage. It often appears as a raised, dome-shaped bump that may be dark brown, black, or even skin-colored. Less common subtypes include acral lentiginous melanoma, which develops on palms, soles, or under nails, and lentigo maligna melanoma, which arises in chronically sun-damaged skin and tends to affect older adults.
Genetic Mutations That Drive Growth
About 38.5% of melanoma patients carry a mutation in the BRAF gene, which acts like a stuck accelerator pedal, sending constant growth signals to tumor cells. Another 16.4% have mutations in NRAS, a related signaling gene, and roughly 10% carry changes in KIT, a gene more commonly mutated in melanomas arising on sun-protected skin, mucous membranes, or acral sites.
These mutations matter for treatment. A BRAF mutation, for example, opens the door to targeted therapies that block that specific growth signal. Your pathology report will typically include mutation testing results, especially for tumors that are thicker or have spread.
Surgery: The First-Line Treatment
For most invasive melanomas, surgery is the primary treatment. The procedure is called wide local excision: the surgeon removes the melanoma along with a margin of normal-looking skin around it. Research comparing narrow margins (1 to 2 cm) to wider ones (3 to 5 cm) has consistently found no difference in survival, disease-free survival, or recurrence rates. Current practice generally calls for a 1 cm margin for melanomas thinner than 1 mm and a 2 cm margin for thicker tumors.
For melanomas deeper than 0.8 mm without ulceration, or thinner than 0.8 mm with ulceration, guidelines recommend a sentinel lymph node biopsy. This procedure identifies the first lymph node that drains the area around the tumor, removes it, and checks it for cancer cells. It doesn’t treat the cancer so much as provide critical staging information that guides further treatment decisions. Even for very thin melanomas under 0.8 mm without ulceration, a sentinel node biopsy may be considered if other high-risk features are present, such as a high mitotic rate or lymphovascular invasion.
Immunotherapy and Targeted Therapy
When invasive melanoma has spread to lymph nodes or distant sites, or when the risk of recurrence is high, systemic therapies come into play. The treatment landscape for advanced melanoma has transformed over the past decade.
Immunotherapy drugs work by releasing the brakes on your immune system so it can recognize and attack melanoma cells. The most commonly used are PD-1 inhibitors like pembrolizumab and nivolumab, which block a protein that melanoma cells exploit to hide from immune detection. Another approach targets CTLA-4, a different checkpoint that keeps immune cells in check. A newer class targets a protein called LAG-3, adding yet another way to activate the immune response. These drugs can be used alone or in combination.
For patients whose tumors carry a BRAF mutation, targeted therapies offer an alternative or complementary approach. These drugs directly block the faulty BRAF protein and the downstream signaling pathway, slowing or stopping tumor growth. They tend to work faster than immunotherapy but may lose effectiveness over time as the cancer develops resistance, which is why they’re sometimes combined with immunotherapy or given in specific sequences.
Survival Rates by Stage
Prognosis depends heavily on how far the melanoma has progressed at the time of diagnosis. According to data from the National Cancer Institute’s SEER program (2015 to 2021), the five-year relative survival rates break down clearly by stage:
- Localized (confined to the skin): 100%
- Regional (spread to nearby lymph nodes): 75.7%
- Distant (metastasized to other organs): 34.6%
That 100% figure for localized disease is remarkable, and it underscores why early detection matters so much. Even regional disease, while more serious, has survival rates that have improved significantly with modern immunotherapy. The distant-stage number, while sobering, also represents a dramatic improvement from just a decade ago, before checkpoint inhibitors became available.
What Follow-Up Looks Like
After treatment, you’ll enter a surveillance schedule designed to catch any recurrence early. The typical pattern at most cancer centers is visits every three months for the first two years, then every six months for years three through five, and annually after that. At each visit, your doctor will carefully examine the surgical scar, the surrounding skin, and the regional lymph nodes.
For stage IA melanoma, the follow-up is less intensive because the recurrence risk is low. Visits may be spaced to every 6 to 12 months, and no imaging is needed beyond a physical exam and your own self-checks. For stage III disease, CT scans of the chest, abdomen, and pelvis play a larger role because they can detect asymptomatic recurrence in about 72% of cases. Patients with stage IIIC melanoma may also receive periodic brain MRI, since the risk of brain metastases exceeds 5% in the first 13 months after treatment.
Regardless of stage, learning to examine your own skin is one of the most valuable things you can do. Regular self-checks of the scar, surrounding skin, and the lymph node areas closest to the original melanoma site catch many recurrences before they would otherwise be found at a scheduled visit.